Mark Schneider, Nestle CEO Future Outlook Companies are adopting diverse strategies, from launching new product lines to utilizing existing ingredients and repositioning current products to cater to the growing GLP-1 companion food market
The MedGuide discusses ONLY the use of tamoxifen to lower the chance of getting breast cancer in high-risk women and in women treated for ductal carcinoma in situ (DCIS), situations in which the risks and benefits of the medicine should be carefully considered
RELATED: Novo Nordisk's new semaglutide trounces Lilly's scrappy Trulicity in diabetes trial Trulicity has seen significant sequential quarter-on-quarter growth, he pointed out, noting that the week prior, the products market share had topped 40% for the first timeand thats despite hefty competition from another Novo weapon, the daily-dosed heavyweight Victoza
None have been independently replicated
And that process which is beneficial to plans, members and the bottom line is uniquely driven by pharmacists with the knowledge to appropriately evaluate the class of drugs, the patients needs, and the costs involved
